Humana Plans To Share Its 2028 Ratings Windfall Rather Than Spend It All
Management is budgeting for sustainable Medicare ratings, while exceptional results could lift earnings above its recovery target.
Humana, which sells health insurance and runs health care services, expects its 2028 Medicare quality-rating benefit to be too large to reinvest usefully, President and Chief Executive Officer Jim Rechtin said on the company’s earnings call Friday. Some will fund temporary investments and some will reach shareholders, while recurring benefits and costs will be budgeted around less exceptional ratings.
Exceptional ratings, restrained spending
Humana’s recovery plan rests on a sustainable Medicare Advantage margin of 3% in 2028. Rechtin said the quality ratings supporting that year’s bonus payments substantially exceed the performance needed to reach that goal, putting the company in position to earn more than its recovery target.
The latest ratings put 95% of members in plans rated four stars or higher, Chief Financial Officer Celeste Mellet said on the call. Rechtin put the member-weighted rating at 4.17, approaching Humana’s highest historical results. Management had already discussed the ratings in an October update.
The distinction for shareholders is between earnings Humana believes it can sustain and an exceptional benefit it expects for 2028. Management wants its ongoing spending to work with ratings around the industry’s top quarter, rather than depend on results in the top tenth.
That leaves room for temporary spending to strengthen quality-rating capabilities, improve members’ experience and deliver better clinical outcomes. But Rechtin set a limit: “we will not be able to productively invest all of it.” Money beyond that capacity would partly pass through to earnings and shareholders.
UBS challenges the ambition gap
An analyst at UBS questioned whether budgeting for the top quarter represented a retreat from Humana’s historical performance, when roughly 90% of membership was consistently in four-star plans. Rechtin acknowledged that history but separated the operating budget from the goal for patient care and ratings.
“Our goal is to be the absolute best that we can be,” Rechtin said. Humana would continue striving for 90% each year, he said, while testing whether its benefits and costs could withstand performance around the top quarter.
Management also wants investors and employees to look beyond the percentage of members in four-star plans. Rechtin said the mix of three-and-a-half-, four- and four-and-a-half-star ratings matters because each step changes revenue per member per month.
Mellet said the top-quarter planning standard had been outlined at last year’s investor day. The approach makes that standard a spending constraint, without making it the ceiling for operating performance.
The stakes are substantial for a company concentrated in government-funded coverage. Federal contracts generated 83% of Humana’s premiums and services revenue during 2025. Alongside its insurance business, CenterWell operates pharmacies, senior-focused primary care and home health care; its primary care business has 350 clinics.
The provider share comes first
The exceptional ratings benefit will not flow entirely to Humana. Mellet cautioned that payments to providers in value-based care arrangements offset 30% of the incremental benefit above the company’s ratings target.
Humana had protected some of those providers when bonus revenue fell, with greater support going to stronger performers. Mellet distinguished a recovery toward the target from performance above it: the excess remains subject to the full 30% provider offset.
The size of the remaining benefit also depends on membership and competitors. Rechtin expects competitors to improve their average scores, narrowing Humana’s advantage relative to its top-quarter benchmark. Membership size and composition, including the next annual enrollment period, will help determine the eventual amount.
Humana then has to judge how much additional investment its operations can absorb productively. Rechtin expects to quantify the benefit and its allocation late next year, or possibly on the fourth-quarter 2027 call. Management will also consider product competition and the regulatory environment.
Recovery extends beyond the ratings
The near-term outlook is improving separately. Mellet raised Humana’s 2026 adjusted earnings forecast to at least $9.50 per share from at least $9.00, with favorable Medicare prescription-drug costs helping drive the increase.
Medical cost growth is running near the lower end of the company’s 7%–8% expectation for this year. For 2027, Humana has priced for overall cost growth of 8%–9%, including prescription-drug cost growth of 14%–15%, which Mellet attributed predominantly to the health technology pipeline.
Pricing for margin was the first priority in designing next year’s plans; retention came second and growth a distant third. Rechtin nevertheless expects membership to rise in 2027, with early enrollment sales and retention of members affected by plan exits exceeding initial expectations.
Mellet said pricing would account for much of the incremental margin progress next year, alongside further operating and medical cost improvements. The group Medicare Advantage business has also improved its margin by 5 percentage points through a substantial contract overhaul, though the full benefit depends on the return of ratings revenue in 2028.
Humana plans to update its 2028 recovery commitments at the December 10 investor event. The larger ratings benefit will be assessed separately from the earnings management considers sustainable.
Sources
- Humana Raises 2026 Earnings Outlook After Third-Quarter Revenue Jumps 26% — Yahoo Finance
- Humana Raises Full-Year Profit Forecast on Lower Medical Costs — Reuters
- Humana Boosts Forecast, Capping Strong Quarter for Insurers (1) — news.bloomberglaw.com
- Humana Aced Its Medicare Ratings. Does It Have an Earnings Ace Up Its Sleeve? — Barron's
- Why Baron Health Care Fund Initiated a Position in Humana (HUM) Amid Trough 2026 Earnings — Yahoo Finance